13G Filing: Baker Bros. Advisors and Anacor Pharmaceuticals, Inc. (ANAC)

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a:

(a) ¨
Broker or dealer registered under Section 15 of the Exchange Act.

(b) ¨
Bank as defined in section 3(a)(6) of the Exchange Act.

(c) ¨
Insurance company as defined in section 3(a)(19) of the Exchange Act.

(d) ¨
Investment company registered under section 8 of the Investment Company Act of 1940.

(e) x
An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

(f) ¨
An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).

(g) x
A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).

(h) ¨
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.

(i) ¨
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act
of 1940.

(j) ¨
Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

 

Item 4.

Ownership.

Items 5 through 9 and 11 of each of the cover pages to this
Amendment No. 2 are incorporated herein reference. Set forth below is the aggregate number of shares of Common Stock the Issuer
directly held by each of Baker Brothers Life Sciences, L.P. (“Life Sciences”), 14159, L.P. (“14159”), and
667, L.P. (“667”, and together with Life Sciences and 14159, the “Funds”) and the percentage of the Issuer’s
outstanding shares of Common Stock such holdings represent. The information set forth below is based upon 44,123,977 shares of
Common Stock outstanding as of October 30, 2015, as reported on the Issuer’s Form 10-Q filed with the SEC on November 6,
2015. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended.